Literature DB >> 15805184

Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan.

Catherine Seyler1, Siaka Toure, Eugène Messou, Dominique Bonard, Delphine Gabillard, Xavier Anglaret.   

Abstract

RATIONALE: In sub-Saharan Africa: (1) tuberculosis is the first cause of HIV-related mortality; (2) the incidence of tuberculosis in adults receiving highly active antiretroviral therapy (HAART) is lower than in untreated HIV-infected adults but higher than in HIV-negative adults; and (3) factors associated with the occurrence of tuberculosis in patients receiving HAART have never been described.
OBJECTIVE: To look for the risk factors for active tuberculosis in HIV-infected adults receiving HAART in Abidjan.
METHODS: Seven-year prospective cohort of HIV-infected adults, with standardized procedures for documenting morbidity. We analyzed the incidence of active tuberculosis in patients who started HAART and the association between the occurrence of tuberculosis and the characteristics of these patients at HAART initiation. MAIN
RESULTS: A total of 129 adults (median baseline CD4 count 125/mm(3)) started HAART and were then followed for 270 person-years (P-Y). At HAART initiation, 31 had a history of tuberculosis and none had current active tuberculosis. During follow-up, the incidence of active tuberculosis was 4.8/100 P-Y (95% confidence interval [CI], 2.5-8.3) overall, 3.0/100 P-Y (95% CI, 1.1-6.6) in patients with no tuberculosis history, and 11.3/100 P-Y (95% CI, 4.1-24.5) in patients with a history of tuberculosis (adjusted hazard ratio, 4.64; 95% CI, 1.29-16.62, p = 0.02).
CONCLUSION: The risk of tuberculosis after HAART initiation was significantly higher in patients with a history of tuberculosis than in those with no tuberculosis history. If confirmed by others, this finding could lead to assessment of new patterns of time-limited tuberculosis secondary chemoprophylaxis during the period of initiation of HAART in sub-Saharan African adults.

Entities:  

Mesh:

Year:  2005        PMID: 15805184     DOI: 10.1164/rccm.200410-1342OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  38 in total

1.  Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies.

Authors:  Annelies Van Rie; Daniel Westreich; Ian Sanne
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04       Impact factor: 3.731

2.  Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting?

Authors:  April C Pettit; Cathy A Jenkins; Samuel E Stinnette; Peter F Rebeiro; Robert B Blackwell; Stephen P Raffanti; Bryan E Shepherd; Timothy R Sterling
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-01       Impact factor: 3.731

3.  Tuberculosis along the continuum of HIV care in a cohort of adolescents living with HIV in Ethiopia.

Authors:  D Jerene; W Abebe; K Taye; P G Suarez; Y Feleke; I Hallström; A J Ruff
Journal:  Int J Tuberc Lung Dis       Date:  2017-01-01       Impact factor: 2.373

4.  Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa.

Authors:  Stephanus Komati; Pamela A Shaw; Nomso Stubbs; Monkwe J Mathibedi; Lizette Malan; Phumelele Sangweni; Julia A Metcalf; Henry Masur; Shaheen Hassim
Journal:  AIDS       Date:  2010-07-31       Impact factor: 4.177

5.  The tuberculosis challenge in a rural South African HIV programme.

Authors:  Catherine F Houlihan; Portia C Mutevedzi; Richard J Lessells; Graham S Cooke; Frank C Tanser; Marie-Louise Newell
Journal:  BMC Infect Dis       Date:  2010-02-10       Impact factor: 3.090

6.  Short and Long-Term Incidence of Tuberculosis and CD4-Cell Count Dynamic on HAART in Senegal.

Authors:  Jean-François Etard; Assane Diouf; Pierre De Beaudrap; Koivugui Akoi; Ndèye Fatou Ngom-Guèye; Ibrahima Ndiaye; René Ecochard; Papa Salif Sow; Delaporte Eric
Journal:  Open AIDS J       Date:  2009-12-31

7.  Risk of tuberculosis among HAART receiving HIV patients attending an ART centre of West Bengal, India: a prospective cohort study.

Authors:  Rajib Saha; Indranil Saha
Journal:  J Community Health       Date:  2014-10

8.  Tuberculosis after one year of combination antiretroviral therapy in Nigeria: a retrospective cohort study.

Authors:  Maxwell O Akanbi; Chad J Achenbach; Joe Feinglass; Babafemi Taiwo; Adamu Onu; Mai T Pho; Oche Agbaji; Phyllis Kanki; Robert L Murphy
Journal:  AIDS Res Hum Retroviruses       Date:  2013-02-25       Impact factor: 2.205

9.  The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome.

Authors:  Yukari C Manabe; Anup K Kesavan; Javier Lopez-Molina; Christine L Hatem; Megan Brooks; Ricardo Fujiwara; Karl Hochstein; M Louise M Pitt; Joann Tufariello; John Chan; David N McMurray; William R Bishai; Arthur M Dannenberg; Susana Mendez
Journal:  Tuberculosis (Edinb)       Date:  2007-12-18       Impact factor: 3.131

Review 10.  Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings.

Authors:  Stephen D Lawn; Katharina Kranzer; Robin Wood
Journal:  Clin Chest Med       Date:  2009-12       Impact factor: 2.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.